Immuno-oncology
Activating the Immune System to Treat Cancer
Heat Biologics
PAO-01-22-R250-06Jan 26, 2022
Cell Therapy
Economically Viable, Same-Day Autologous Cell Therapies
Gregory Frost, Ph.D.; Sid Kerkar, M.D.
EXUMA Biotechnology
PAO-01-21-CL-06Feb 04, 2021
M&A
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Astellas
PR-M01-20-NI-006Jan 03, 2020
Immunotherapy
Collaborating for Immunotherapy Development
KshitiJ (TJ) Ladage
Nice Insight
PAP-Q1-2019-NI-007Mar 12, 2019
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
Nice Insight
PAO-M01-19-NI-012Jan 09, 2019
Immuno-Oncology
FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies
FIMECS, Inc.
PR-M04-18-NI-44Apr 13, 2018
Immuno-oncology
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
Allogene Therapeutics
PR-M04-18-NI-40Apr 12, 2018
Immuno-Oncology
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
Boehringer Ingelheim
PR-M04-18-NI-030Apr 10, 2018
Immuno-Oncology
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
PR-M01-18-NI-082Jan 25, 2018
Acquisition
Charles River Laboratories Continues to Grow Through Acquisition
Nigel Walker
Nice Insight
PAO-M01-18-NI-035Jan 19, 2018
Drug Development
Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs
Potenza Therapeutics, Inc.
PR-M01-18-NI-024Jan 10, 2018
Business
Cue Biopharma Announces Closing of Initial Public Offering
Cue Biopharma
PR-M01-18-NI-003Jan 02, 2018
Immuno-Oncology Therapies
ARMO BioSciences Files Registration Statement for Proposed Initial Public Offering
ARMO BioSciences, Inc
PR-M01-18-NI-001Jan 02, 2018
Drug Development
Memory T Cells Fit to be Cross Trained
Nice Insight
PAO-M12-17-NI-027Dec 19, 2017
Oncology
Altering White Blood Cells to Kill Cancer
Nigel Walker
Nice Insight
PAO-M12-17-NI-026Dec 19, 2017
Innovation
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
Bristol-Myers Squibb
PR-M12-17-NI-015Dec 15, 2017
Immuno-oncology
Genentech and Biothera to Assess Combination Cancer Therapy
Nice Insight
PAO-M12-17-NI-010Dec 08, 2017
Immuno-oncology
Immuno-oncology Approach Based on Electronic Circuitry
Guy Tiene
Nice Insight
PAO-M11-17-NI-008Nov 03, 2017
Oncology
Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
Nice Insight
PAO-M08-17-NI-015Aug 11, 2017
Drug Development
New Partnership Targets Colorectal Cancer with Combination Therapy, Including Avelumab
Guy Tiene
Nice Insight
PAO-M06-17-NI-020Jun 29, 2017